<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00852566</url>
  </required_header>
  <id_info>
    <org_study_id>2008-004106-13</org_study_id>
    <nct_id>NCT00852566</nct_id>
  </id_info>
  <brief_title>Randomized Study Comparing the Effect of Dasatinib and Imatinib on Malignant Stem Cells in Chronic Myeloid Leukemia</brief_title>
  <acronym>NordCML006</acronym>
  <official_title>An Open-Label, Randomized, Multicenter Phase II Trial Comparing the Depletion of Malignant Stem Cells With Dasatinib vs. Imatinib in Patients With Newly Diagnosed Chronic Phase Chronic Myeloid</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Norwegian University of Science and Technology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Norwegian University of Science and Technology</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized multi-center study comparing the effect of dasatinib and imatinib on malignant&#xD;
      stem cells in newly diagnosed chronic phase chronic myeloid leukemia (CML) patients. The&#xD;
      research hypothesis is that treatment with dasatinib 100 mg daily (QD) results in greater and&#xD;
      more rapid depletion of the Philadelphia (Ph) -positive stem cell pool within 6 months of&#xD;
      therapy than imatinib 400 mg QD in newly diagnosed CML patients. The study duration is 18&#xD;
      months and approximately 40 patients will be recruited to the study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An Open-Label, Randomized, Multicenter Phase II Trial Comparing the depletion of malignant&#xD;
      stem cells with Dasatinib vs. Imatinib in Patients with Newly Diagnosed Chronic Phase Chronic&#xD;
      Myeloid Leukemia&#xD;
&#xD;
      Estimated Number of Study Centers and Countries/Regions: Appr. 12 sites in 5 Nordic&#xD;
      countries. Stem cell analyses will be performed in 4 Nordic centers (Helsinki, Lund, Oslo and&#xD;
      Stockholm).&#xD;
&#xD;
      Study Phase: II&#xD;
&#xD;
      Research Hypothesis: Treatment with dasatinib 100 mg daily (QD) results in greater and more&#xD;
      rapid depletion of the Philadelphia (Ph) -positive stem cell pool within 6 months of therapy&#xD;
      than imatinib 400 mg QD in newly diagnosed chronic phase (CP) chronic myeloid leukemia (CML)&#xD;
      patients.&#xD;
&#xD;
      Primary Objective: To compare the number of Ph-positive cells in the stem cell compartment in&#xD;
      newly diagnosed CP CML patients treated with dasatinib 100 mg QD vs. imatinib 400 mg QD.&#xD;
&#xD;
      Study Design: open-label randomized Phase II trial in newly diagnosed CML patients in CP.&#xD;
      Patients will be randomized to receive dasatinib at a starting dose of 100 mg QD or imatinib&#xD;
      at a starting dose of 400 mg QD.&#xD;
&#xD;
      Duration of Study: The study will be open for enrollment until the planned number of 40&#xD;
      patients is randomized. All patients will be treated and/or followed for up to 18 months.&#xD;
      Based on the amendment 1 (Oct 2011), the follow-up of the patients will continue additional 4&#xD;
      years until 31.12.2015.&#xD;
&#xD;
      Number of Patients per Group: Approximately 40 patients will be randomized, 20 patients to&#xD;
      dasatinib and 20 to imatinib. Additional patients will be recruited in case insufficient&#xD;
      amount of representative samples have been obtained from first 40 patients.&#xD;
&#xD;
      Study Population: Patients 18 years or older with a newly diagnosed CP CML, not previously&#xD;
      treated with any systemic treatments for CML&#xD;
&#xD;
      Study Assessments and Endpoints:&#xD;
&#xD;
      All stem cell assays are based on the preselection of CD34+ cells from large volume of bone&#xD;
      marrow (BM) aspirates using paramagnetic beads. The CD34+ fraction will be further subdivided&#xD;
      based on the expression of CD38 marker (positive vs. negative) using a sorting flow&#xD;
      cytometer.&#xD;
&#xD;
      The primary endpoint is a comparison of proportion of Ph-positive cells in stem cell&#xD;
      compartments (CD34+CD38neg and CD34+CD38+) at 6 months between the study arms.&#xD;
&#xD;
      Secondary endpoints are comparisons between treatment arms for: (1) the number of Ph-positive&#xD;
      cells in all stem cell compartments at 1 and 3 months, (2) BCR-ABL RQ-PCR in blood at 1, 3,&#xD;
      6, 12 and 18 months, and (3) rate of CCyR within 3, 6, 12 and 18 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 2009</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">February 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ph-positive cells in stem cell compartments</measure>
    <time_frame>6 months</time_frame>
    <description>proportion of Ph-positive cells in stem cell compartments (CD34+CD38neg and CD34+CD38+)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>BCR-ABL RQ-PCR in blood</measure>
    <time_frame>up to 18 months (1, 3, 6, 12 and 18 months)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Chronic Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Imatinib</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard treatment Imatinib 400mg OD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>dasatinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dasatinib 100mg OD</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imatinib</intervention_name>
    <description>Per oral imatinib 400mg once daily (continuous medication)</description>
    <arm_group_label>Imatinib</arm_group_label>
    <other_name>Glivec</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dasatinib</intervention_name>
    <description>Per oral dasatinib 100mg once daily (continuous medication)</description>
    <arm_group_label>dasatinib</arm_group_label>
    <other_name>Sprycel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients are able to provide written informed consent&#xD;
&#xD;
          -  Patients must have CML in CP which is defined by the presence of all of the following&#xD;
             criteria:&#xD;
&#xD;
               -  &lt; 15% blasts in peripheral blood (PB) and BM.&#xD;
&#xD;
               -  &lt; 30% blasts plus promyelocytes in PB and BM.&#xD;
&#xD;
               -  &lt; 20% basophils in the PB.&#xD;
&#xD;
               -  ≥ 100 x 109/L platelets.&#xD;
&#xD;
               -  No evidence of extramedullary leukemia apart from hepatosplenomegaly&#xD;
&#xD;
               -  Ph+ or variants must be demonstrated by BM cytogenetics, FISH or PCR.&#xD;
&#xD;
               -  Previously untreated CML in CP, with the exception of hydroxyurea or anagrelide&#xD;
&#xD;
          -  Patients must be enrolled in this study within 90 days after the date of first being&#xD;
             diagnosed with CML&#xD;
&#xD;
          -  ECOG Performance Status (PS) Score 0 - 1 (see Appendix 2)&#xD;
&#xD;
          -  Adequate hepatic function defined as: total bilirubin ≤ 2.0 times the institutional&#xD;
             upper limit of normal (ULN) in absence of Gilbert type unconjugated&#xD;
             hyperbilirubinemia; alanine aminotransferase (ALAT≤ 2.5 times the institutional ULN.&#xD;
&#xD;
          -  Adequate renal function defined as serum creatinine ≤ 2 times the institutional ULN.&#xD;
&#xD;
          -  Men and women, ages 18 years and older.&#xD;
&#xD;
          -  Adequate BM aspiration sample before the start of study treatment (i.e sample is&#xD;
             sufficient for stem cell analysis)&#xD;
&#xD;
          -  Potentially fertile women must use an adequate method of contraception to avoid&#xD;
             pregnancy throughout the study.&#xD;
&#xD;
          -  Potentially fertile women must have a negative serum or urine pregnancy test&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Fertile women who are unwilling or unable to use an acceptable method to avoid&#xD;
             pregnancy for the entire study&#xD;
&#xD;
          -  Women who are pregnant or breastfeeding.&#xD;
&#xD;
          -  Men with fertile sexual partners who can or will not use an acceptable contraception&#xD;
             method for the entire study&#xD;
&#xD;
          -  A serious uncontrolled medical disorder or active infection that would impair the&#xD;
             ability of the subject to receive protocol therapy.&#xD;
&#xD;
          -  Known pleural effusion at baseline.&#xD;
&#xD;
          -  Uncontrolled or significant cardiovascular disease&#xD;
&#xD;
          -  History of significant bleeding disorder unrelated to CML, including:&#xD;
&#xD;
          -  Prior chemotherapy for peripheral stem cell mobilization.&#xD;
&#xD;
          -  Inadequate BM aspiration sample due to marrow fibrosis or other reasons&#xD;
&#xD;
          -  Prior or concurrent malignancy&#xD;
&#xD;
          -  Severe psychiatric illness, imprisonment or mental impairment inflicting on ability to&#xD;
             give informed consent&#xD;
&#xD;
          -  Abuse of alcohol, prescribed or illicit drugs&#xD;
&#xD;
          -  Evidence of digestive dysfunction that would prevent administration of study therapy&#xD;
             by mouth.&#xD;
&#xD;
          -  Prohibited Treatments and/or Therapies&#xD;
&#xD;
               -  Any prior treatment with interferon&#xD;
&#xD;
               -  Any prior treatment with dasatinib&#xD;
&#xD;
               -  Any prior treatment with imatinib&#xD;
&#xD;
               -  Any other prior systemic treatments, with anti-CML activity [except for&#xD;
                  anagrelide, or hydroxyurea (HU)].&#xD;
&#xD;
          -  Patients currently taking drugs that are generally accepted to have a risk of causing&#xD;
             Torsades de Pointes as described in Appendix 3.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Satu Mustjoki, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Helsinki University Central Hospital, helsinki, Finland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Henrik Hjorth-Hansen, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>St Olavs Hospital, Trondheim, Norway</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ole Weiss-Bjerrum, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Rigshospitalet, Denmark</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ingunn Dybedal, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Rikshospitalet, Oslo, Norway</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tobias Gedde-Dahl, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Rikshospitalet, Oslo, Norway</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kimmo Porkka, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Helsinki University Central Hospital, Helsinki, Finland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Johan Richter, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Lund, Lund, Sweden</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bengt Simonsson, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital, Uppsala, Sweden</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Leif Stenke, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Karolinska Institutet</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Helsinki University Central Hospital</name>
      <address>
        <city>Helsinki</city>
        <zip>00029</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bergen University Central Hospital</name>
      <address>
        <city>Bergen</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rikshospitalet</name>
      <address>
        <city>Oslo</city>
        <zip>0027</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Olavs Hospital</name>
      <address>
        <city>Trondheim</city>
        <zip>7006</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lund University Hospital</name>
      <address>
        <city>Lund</city>
        <zip>22185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <zip>17176</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uppsala University Hospital</name>
      <address>
        <city>Uppsala</city>
        <zip>75185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
    <country>Norway</country>
    <country>Sweden</country>
  </location_countries>
  <results_reference>
    <citation>Hjorth-Hansen H, Stenke L, Söderlund S, Dreimane A, Ehrencrona H, Gedde-Dahl T, Gjertsen BT, Höglund M, Koskenvesa P, Lotfi K, Majeed W, Markevärn B, Ohm L, Olsson-Strömberg U, Remes K, Suominen M, Simonsson B, Porkka K, Mustjoki S, Richter J; Nordic CML Study Group. Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006). Eur J Haematol. 2015 Mar;94(3):243-50. doi: 10.1111/ejh.12423. Epub 2014 Sep 13.</citation>
    <PMID>25082346</PMID>
  </results_reference>
  <verification_date>September 2017</verification_date>
  <study_first_submitted>February 26, 2009</study_first_submitted>
  <study_first_submitted_qc>February 26, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 27, 2009</study_first_posted>
  <last_update_submitted>September 21, 2017</last_update_submitted>
  <last_update_submitted_qc>September 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic myeloid leukemia</keyword>
  <keyword>tyrosine kinase inhibitor</keyword>
  <keyword>stem cell</keyword>
  <keyword>Philadelphia chromosome</keyword>
  <keyword>dasatinib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Imatinib Mesylate</mesh_term>
    <mesh_term>Dasatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

